Inferior Vena Cava Diameter in Patients with Chronic Heart Failure and Chronic Kidney Disease: a Retrospective Study

Overview

Journal Eur J Med Res

Publisher Biomed Central

Date 2025 Jan 14

PMID 39810195

Authors

Jianan Li

Chi Wang

Hui Wu Dong

Jing Qi

Chongyou Rao

Qiuyang Li

Kunlun He

Affiliations

Soon will be listed here.

Abstract

Background: Chronic kidney disease (CKD) carries the highest population attributable risk for mortality among all comorbidities in chronic heart failure (CHF). No studies about the association between inferior vena cava (IVC) diameter and all-cause mortality in patients with the comorbidity of CKD and CHF has been published.

Methods: In this retrospective cohort study, a total of 1327 patients with CHF and CKD were included. All patients underwent standardized echocardiography examination and data on demographic characteristics, medical history, and laboratory tests were recorded. Information on all-cause mortality was collected by telephone interview and medical records review. We used Cox regression to evaluate the risk of all-cause mortality among groups, and used mediation analysis to examine the mediation role of N-terminal-pro-B-type natriuretic peptide (NT-proBNP) and serum albumin in the association between IVC and all-cause mortality.

Results: During a median follow-up of 3.46 years (IQR: 1.55-5.15 years), 757 (57.05%) cases of all-cause mortality were observed. Compared with patients with IVC diameter < 21 mm, those with IVC diameter > 21 mm were associated with higher risk of all-cause mortality (HR (95%CI):1.31(1.07-1.61), log rank: P = 0.01) and cardiovascular mortality (HR (95%CI): 1.55(1.19-2.04), log rank: P = 0.001). When assessing IVC as a continuous variable, each 1% increase in IVC was associated with 4% increased risk of all-cause mortality (HR: 1.04, 95%CI 1.02-1.06, P < 0.001). This association were mediated by log NT-proBNP (mediated effect: 37.8% (95%CI 22.0-73.0%), P < 0.001) and serum albumin (mediated effect: 14.1% (95%CI 6.2-28.0%), P < 0.001). In subgroup analyses, there was no significant interaction in different subgroups of cardiac and renal function for the association between IVC and all-cause mortality.

Conclusions: Elevated IVC diameter was associated with worse prognosis in patients with CHF and CKD, and the associations were mediated by log NT-proBNP and serum albumin.

References

. Recommendations for Cardiac Chamber Quantification by Echocardiography in Adults: An Update from the American Society of Echocardiography and the European Association of, Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 2016; 17(4):412. DOI: 10.1093/ehjci/jew041. View

van der Meer P, Gaggin H, Dec G . ACC/AHA Versus ESC Guidelines on Heart Failure: JACC Guideline Comparison. J Am Coll Cardiol. 2019; 73(21):2756-2768. DOI: 10.1016/j.jacc.2019.03.478. View

Gori M, Senni M, Gupta D, Charytan D, Kraigher-Krainer E, Pieske B . Association between renal function and cardiovascular structure and function in heart failure with preserved ejection fraction. Eur Heart J. 2014; 35(48):3442-51. PMC: 4810804. DOI: 10.1093/eurheartj/ehu254. View

Pellicori P, Carubelli V, Zhang J, Castiello T, Sherwi N, Clark A . IVC diameter in patients with chronic heart failure: relationships and prognostic significance. JACC Cardiovasc Imaging. 2013; 6(1):16-28. DOI: 10.1016/j.jcmg.2012.08.012. View

Hillege H, Nitsch D, Pfeffer M, Swedberg K, McMurray J, Yusuf S . Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation. 2006; 113(5):671-8. DOI: 10.1161/CIRCULATIONAHA.105.580506. View

Sallach J, Tang W, Borowski A, Tong W, Porter T, Martin M . Right atrial volume index in chronic systolic heart failure and prognosis. JACC Cardiovasc Imaging. 2009; 2(5):527-34. DOI: 10.1016/j.jcmg.2009.01.012. View

Janse R, Fu E, Dahlstrom U, Benson L, Lindholm B, van Diepen M . Use of guideline-recommended medical therapy in patients with heart failure and chronic kidney disease: from physician's prescriptions to patient's dispensations, medication adherence and persistence. Eur J Heart Fail. 2022; 24(11):2185-2195. PMC: 10087537. DOI: 10.1002/ejhf.2620. View

Bursi F, McNallan S, Redfield M, Nkomo V, Lam C, Weston S . Pulmonary pressures and death in heart failure: a community study. J Am Coll Cardiol. 2012; 59(3):222-31. PMC: 3258551. DOI: 10.1016/j.jacc.2011.06.076. View

Sampath-Kumar R, Ben-Yehuda O . Inferior vena cava diameter and risk of acute decompensated heart failure rehospitalisations. Open Heart. 2023; 10(2). PMC: 10496688. DOI: 10.1136/openhrt-2023-002331. View

10.

Schefold J, Filippatos G, Hasenfuss G, Anker S, von Haehling S . Heart failure and kidney dysfunction: epidemiology, mechanisms and management. Nat Rev Nephrol. 2016; 12(10):610-23. DOI: 10.1038/nrneph.2016.113. View

11.

Schaub J, Coca S, Moledina D, Gentry M, Testani J, Parikh C . Amino-Terminal Pro-B-Type Natriuretic Peptide for Diagnosis and Prognosis in Patients With Renal Dysfunction: A Systematic Review and Meta-Analysis. JACC Heart Fail. 2015; 3(12):977-89. PMC: 4683413. DOI: 10.1016/j.jchf.2015.07.014. View

12.

Drazner M . Is the inferior vena cava really superior?. JACC Cardiovasc Imaging. 2013; 6(1):29-31. DOI: 10.1016/j.jcmg.2012.11.001. View

13.

Bourantas C, Loh H, Bragadeesh T, Rigby A, Lukaschuk E, Garg S . Relationship between right ventricular volumes measured by cardiac magnetic resonance imaging and prognosis in patients with chronic heart failure. Eur J Heart Fail. 2010; 13(1):52-60. DOI: 10.1093/eurjhf/hfq161. View

14.

Zannad F, Rossignol P . Cardiorenal Syndrome Revisited. Circulation. 2018; 138(9):929-944. DOI: 10.1161/CIRCULATIONAHA.117.028814. View

15.

. 2. Classification and Diagnosis of Diabetes: . Diabetes Care. 2020; 44(Suppl 1):S15-S33. DOI: 10.2337/dc21-S002. View

15.

Gerhardt L, Kordsmeyer M, Sehner S, Guder G, Stork S, Edelmann F . Prevalence and prognostic impact of chronic kidney disease and anaemia across ACC/AHA precursor and symptomatic heart failure stages. Clin Res Cardiol. 2022; 112(7):868-879. PMC: 10293329. DOI: 10.1007/s00392-022-02027-w. View

16.

Inker L, Eneanya N, Coresh J, Tighiouart H, Wang D, Sang Y . New Creatinine- and Cystatin C-Based Equations to Estimate GFR without Race. N Engl J Med. 2021; 385(19):1737-1749. PMC: 8822996. DOI: 10.1056/NEJMoa2102953. View

17.

Goonewardena S, Blair J, Manuchehry A, Brennan J, Keller M, Reeves R . Use of hand carried ultrasound, B-type natriuretic peptide, and clinical assessment in identifying abnormal left ventricular filling pressures in patients referred for right heart catheterization. J Card Fail. 2010; 16(1):69-75. DOI: 10.1016/j.cardfail.2009.08.004. View

18.

Szlagor M, Dybiec J, Mlynarska E, Rysz J, Franczyk B . Chronic Kidney Disease as a Comorbidity in Heart Failure. Int J Mol Sci. 2023; 24(3). PMC: 9918100. DOI: 10.3390/ijms24032988. View

19.

McEvoy J, Daya N, Rahman F, Hoogeveen R, Blumenthal R, Shah A . Association of Isolated Diastolic Hypertension as Defined by the 2017 ACC/AHA Blood Pressure Guideline With Incident Cardiovascular Outcomes. JAMA. 2020; 323(4):329-338. PMC: 6990938. DOI: 10.1001/jama.2019.21402. View